antibody levels and vaccination attitude after asymptomatic to moderate

omniscientis

omniscientis

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic

 

Regardless of substantial progress in confronting the worldwide HIV-1 epidemic since its inception within the 1980s, higher approaches for each therapy and prevention will probably be obligatory to finish the epidemic and stay a high public well being precedence. Antiretroviral remedy (ART) has been efficient in extending lives, however at a price of lifelong adherence to therapy. Broadly neutralizing antibodies (bNAbs) are directed to conserved areas of the HIV-1 envelope glycoprotein trimer (Env) and may block an infection if current on the time of viral publicity. The therapeutic software of bNAbs holds nice promise, and progress is being made towards their growth for widespread medical use. In comparison with the present customary of care of small molecule-based ART, bNAbs supply: (1) decreased toxicity; (2) the benefits of prolonged half-lives that might bypass day by day dosing necessities; and (3) the potential to include a wider immune response by Fc signaling. Latest advances in discovery expertise can allow system-wide mining of the immunoglobulin repertoire and can proceed to speed up isolation of subsequent era potent bNAbs. Passive switch research in pre-clinical fashions and medical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and attaining viral suppression.

These research have helped to outline the window of alternative for optimum intervention to realize viral clearance, both utilizing bNAbs alone or together with ART. None of those advances with bNAbs can be doable with out technological developments and increasing the cohorts of donor participation. Collectively these components fueled the exceptional development in bNAb growth. Right here, we evaluation the event of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal fashions and early medical trials, and improvements to optimize their medical potential by efforts to increase half-life, maximize the contribution of Fc effector capabilities, preclude escape by multiepitope concentrating on, and the potential for sustained supply.

 

Signs, antibody ranges and vaccination perspective after asymptomatic to reasonable COVID-19 an infection in 200 healthcare employees

 

Purpose: In Germany, the willingness to be vaccinated towards COVID-19 is slightly low amongst medical workers. We collected information on signs, antibody titers and vaccination readiness from clinic workers at a municipal clinic who had already been by a COVID-19 an infection (asymptomatic to reasonable). We additionally examined the antibody titers for his or her doable significance as a person decision-making assist with regard to vaccination.

 

Technique: 200 workers of our municipal clinics have been included within the research. COVID-19 antibody dedication was carried out utilizing an ELISA (EUROIMMUN™, PerkinElmer, Inc. Firm). The individuals got an nameless questionnaire containing anthropometrical points, signs of the an infection and questions in regards to the vaccination resolution. Lastly, the antibody ranges have been reported to the individuals and the perspective in the direction of a vaccination was reevaluated.

 

Outcomes: In all 200 individuals who had already gone by a COVID-19 an infection, 75 workers have been in favor of a vaccination (37.5%), 96 have been against vaccination (48%), and 29 have been undecided (14.5%). Within the completely different occupational teams, the constructive pattern by way of willingness to be vaccinated was highest amongst physicians and is least amongst nurses. The antibody outcomes confirmed appreciable variation in titer ranges and subsequently didn’t correlate with illness severity in asymptomatic to reasonably in poor health individuals. We additionally noticed a pro-vaccination pattern with rising age of the individuals. The specifically-asked symptom of cutaneous hyperesthesia throughout COVID-19 an infection occurred in 5% of the individuals.

 

Conclusion: In medical personnel who had already suffered from a COVID-19 an infection, the willingness to obtain a vaccination tends to be highest amongst physicians, and lowest in nurses, and will increase with age. For the overwhelming majority of these affected, data of the antibody titers solely reinforces the vaccination resolution made beforehand and thus doesn’t contribute to a change in vaccination resolution. The specifically-requested symptom of cutaneous hyperesthesia throughout COVID-19 an infection was unexpectedly frequent.

omniscientis
omniscientis

VEGF-A(VEGF/1063) Antibody

BNC551063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC431063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC431063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC471063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC471063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC801063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC801063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC811063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC811063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC611063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC611063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNUM1063-50 50uL
EUR 474
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCB1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCB1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCP1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC941063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC941063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCAP1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCAP1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCA1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCH1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCH1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNUB1063-100 100uL
EUR 250.8
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody

BNUB1063-500 500uL
EUR 549.6
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody

BNC041063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC041063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC051063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC051063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC701063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC701063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC881063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC881063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC681063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC681063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCR1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL

Anti-VEGF/Vegfa Antibody

A00045 100ug/vial
EUR 352.8

Anti-VEGF/Vegfa Antibody

A00045-2 100ug/vial
EUR 352.8

Anti-VEGF/VEGFA Antibody

PA1080 100ug/vial
EUR 400.8

Anti-VEGF/VEGFA Antibody

PB9071 100ug/vial
EUR 400.8

VEGF Antibody

5363-100 each
EUR 398.4

VEGF Antibody

5363-30T each
EUR 175.2

VEGF Antibody

5365-100 each
EUR 379.2

VEGF Antibody

5365-30T each
EUR 175.2

VEGF antibody

70R-11863 100 ul
EUR 536.4
Description: Goat polyclonal VEGF antibody

VEGF antibody

70R-11864 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-12327 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-12328 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-12329 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-13764 100 ug
EUR 418.8
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70-VR20 50 ug
EUR 392.4
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF Antibody

48707-100ul 100ul
EUR 399.6

VEGF Antibody

48707-50ul 50ul
EUR 286.8

VEGF antibody

10-2585 250 ug
EUR 590.4
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10-2586 100 ug
EUR 289.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V101ax 100 ug
EUR 571.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V101b 200 ug
EUR 805.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V109A 500 ug
EUR 327.6
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-7735 500 ug
EUR 678
Description: Mouse monoclonal VEGF antibody

VEGF antibody

70R-VG001 100 ug
EUR 392.4
Description: Affinity purified Goat polyclonal VEGF antibody

VEGF antibody

70R-VR001x 50 ug
EUR 392.4
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR003 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR004 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR006 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF Antibody

ABF5131 100 ug
EUR 525.6

VEGF antibody

PAab09933 100 ug
EUR 463.2

VEGF Antibody

R31500 100 ug
EUR 356.15
Description: VEGF is the only mitogen that specifically acts on endothelial cells. It may be a major regulator of tumor angiogenesis in vivo. It is structurally related to platelet-derived growth factor. VEGF shares homology with the PDGF A chain and B chain, including conservation of all 8 cysteines found in PDGFA and PDGFB. VEGF gene contains 8 exons. VEGF induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. And this gene also can regulate haematopoietic stem cell survival by an internal autocrine loop mechanism. What’s more, it also stimulates neurogenesis in vitro and in vivo.

VEGF Antibody

V8154-100UG 100 ug
EUR 349.3
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

VEGF Antibody

V8154-20UG 20 ug
EUR 153.3
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

VEGF Antibody

V8154SAF-100UG 100 ug
EUR 349.3
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

VEGF/ Rat VEGF ELISA Kit

ELA-E0143r 96 Tests
EUR 1063.2

VEGF

LF-PR009 10 ug
EUR 306
Description: VEGF protein

VEGF

MO15067 500 ug
EUR 1092

VEGF

PR15028 10 ug
EUR 553.2

VEGF 121

PR15029 5 ug
EUR 498

VEGF 162

PR15030 25 ug
EUR 553.2

VEGF 165

PR15031 50 ug
EUR 1477.2

VEGF 120

PR15033 5 ug
EUR 459.6

VEGF 164

PR15034 25 ug
EUR 1352.4

VEGF 164

PR15035 50 ug
EUR 1477.2

Human VEGF 121 Antibody

32562-05111 150 ug
EUR 313.2

Human VEGF 165 Antibody

32563-05111 150 ug
EUR 313.2

EG VEGF antibody

70R-EG002 50 ug
EUR 327.6
Description: Affinity purified Goat polyclonal EG VEGF antibody

EG VEGF antibody

20R-1607 100 ug
EUR 807.6
Description: Rabbit polyclonal EG VEGF antibody

VEGF C antibody

20R-1831 100 ug
EUR 807.6
Description: Goat polyclonal VEGF C antibody

VEGF-C Antibody

5633-100 each
EUR 444

VEGF-C Antibody

5633R-100 each
EUR 379.2

VEGF-C Antibody

5633R-30T each
EUR 175.2

VEGF-C Antibody

5634-100 each
EUR 379.2

VEGF-C Antibody

5634-30T each
EUR 175.2

VEGF-B Antibody

5641-100 each
EUR 379.2

VEGF-B Antibody

5641-30T each
EUR 175.2

VEGF-D Antibody

5643-100 each
EUR 379.2

VEGF-D Antibody

5643-30T each
EUR 175.2

VEGF-A Antibody

F41972-0.08ML 0.08 ml
EUR 140.25
Description: This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms.

VEGF-A Antibody

F41972-0.4ML 0.4 ml
EUR 322.15
Description: This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms.

VEGF-C Antibody

F47901-0.4ML 0.4 ml
EUR 322.15
Description: VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D.

VEGF-A/ Rat VEGF- A ELISA Kit

ELA-E1851r 96 Tests
EUR 1063.2

VEGF-B/ Rat VEGF- B ELISA Kit

ELA-E0144r 96 Tests
EUR 1063.2

VEGF-C/ Rat VEGF- C ELISA Kit

ELA-E0145r 96 Tests
EUR 1063.2

VEGF-D/ Rat VEGF- D ELISA Kit

ELA-E0146r 96 Tests
EUR 1063.2

human VEGF Antibody

E13-a001 100μg
EUR 458.4

Polyclonal VEGFA / VEGF Antibody

APR10713G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VEGFA / VEGF . This antibody is tested and proven to work in the following applications:

VEGF antibody (biotin)

60R-1093 25 ug
EUR 327.6
Description: Rabbit monoclonal VEGF antibody (biotin)

VEGF antibody (biotin)

60R-V101cBT 50 ug
EUR 392.4
Description: Rabbit polyclonal VEGF antibody (biotin) conjugated

VEGF antibody (biotin)

60R-VG001bt 50 ug
EUR 457.2
Description: Goat polyclonal VEGF antibody (biotin) conjugated

VEGF antibody (biotin)

60R-VR001bt 50 ug
EUR 327.6
Description: Rabbit polyclonal VEGF antibody (biotin) conjugated

VEGF, CF

PR15028CF 10 ug
EUR 553.2

Rabbit Anti-Common N. American (Diamondback, copperhead and Mocacassin snakes) venom antiserum

CATX15-S 100 ul
EUR 548.4

Chicken Anti-Common N. American (Diamondback, copperhead and Mocacassin snakes) venom antiserum

CATX16-S 100 ul
EUR 548.4

Sheep Anti-Common N. American (Diamondback, copperhead and Mocacassin snakes) venom antiserum

CATX17-S 100 ul
EUR 548.4

VEGF Receptor Antibody

R31072 100 ug
EUR 356.15
Description: Vascular endothelial growth factor receptor 1(FLT1) is a protein that in humans is encoded by the FLT1 gene. Oncogene FLT belongs to the src gene family. Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation.

VEGF-C

PR27170 2 ug
EUR 229.2

VEGF-B

RA26004 100 ul
EUR 646.8

VEGF-D

RA26005 100 ul
EUR 646.8

Goat(VEGF)

QY-E140039 96T
EUR 495.6

VEGF 121, CF

PR15029CF 5 ug
EUR 498

VEGF 162, CF

PR15030CF 25 ug
EUR 553.2

VEGF 165, CF

PR15031CF 50 ug
EUR 1477.2

VEGF 164, CF

PR15034CF 5 ug
EUR 459.6

VEGF 164, CF

PR15035CF 50 ug
EUR 1477.2

rHu VEGF-165

AK8295-0002 2µg Ask for price

rHu VEGF-165

AK8295-0010 10µg Ask for price

rHu VEGF-165

AK8295-0100 100µg Ask for price

rHu VEGF-165

AK8295-1000 1mg Ask for price

rHu VEGF-121

AK8331-0002 2µg Ask for price

rHu VEGF-121

AK8331-0010 10µg Ask for price

rHu VEGF-121

AK8331-0100 100µg Ask for price

rHu VEGF-121

AK8331-1000 1mg Ask for price

VEGF Polyclonal Antibody

A72296
  • EUR 302.50
  • EUR 423.50
  • 50 ul
  • 100 ul

Polyclonal VEGF Antibody

APR10709G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VEGF . This antibody is tested and proven to work in the following applications:

Polyclonal VEGF Antibody

APR10710G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VEGF . This antibody is tested and proven to work in the following applications:

VEGF Monoclonal Antibody

30217-100ul 100ul
EUR 302.4

VEGF Monoclonal Antibody

30217-50ul 50ul
EUR 224.4

VEGF Conjugated Antibody

C48707 100ul
EUR 476.4

VEGF Polyclonal Antibody

EA320-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against VEGF from Human/ Rat/ Mouse. This antibody is tested and validated for IHC

VEGF Polyclonal Antibody

EA320-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against VEGF from Human/ Rat/ Mouse. This antibody is tested and validated for IHC

VEGF-121-Fc

E13-m005-1 10μg
EUR 411.6

VEGF-121-Fc

E13-m005-2 50μg
EUR 1386

VEGF-165-Fc

E13-m006-1 10μg
EUR 411.6

VEGF-165-Fc

E13-m006-2 50μg
EUR 1386

Genorise® Anti-canine VEGF Polyclonal Antibody

GR105177 100 ug
EUR 438

Genorise® Anti-Equine VEGF Polyclonal Antibody

GR105195 100 ug
EUR 438

VEGF protein

30R-AV008 2 ug
EUR 152.4
Description: Purified recombinant Murine VEGF protein

Insulin-US Standard F

F282F 1 ml
EUR 234
Description: Insulin-US Standard F by Cygnus Technologies is available in Europe via Gentaur.

VEGF Receptor 1 / VEGFR1 Antibody

RQ4032 100 ug
EUR 356.15
Description: Vascular endothelial growth factor receptor 1 (FLT1) is a protein that in humans is encoded by the FLT1 gene. Oncogene FLT belongs to the src gene family. It is mapped to 13q12. The deduced 1,338-amino acid protein has a calculated molecular mass of 150.6 kD. It has a 758-amino acid extracellular domain, followed by a 22-amino acid transmembrane region and a 558-amino acid cytoplasmic region containing a cluster of basic amino acids and a tyrosine kinase domain. sFLT-1 was identified in placenta, adult lung, kidney, liver and uterus. Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation.

VEGF Receptor 1 / VEGFR1 Antibody

RQ4033 100 ug
EUR 356.15
Description: Vascular endothelial growth factor receptor 1 (FLT1) is a protein that in humans is encoded by the FLT1 gene. Oncogene FLT belongs to the src gene family. It is mapped to 13q12. The deduced 1,338-amino acid protein has a calculated molecular mass of 150.6 kD. It has a 758-amino acid extracellular domain, followed by a 22-amino acid transmembrane region and a 558-amino acid cytoplasmic region containing a cluster of basic amino acids and a tyrosine kinase domain. sFLT-1 was identified in placenta, adult lung, kidney, liver and uterus. Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation.

VEGF Receptor 3 Antibody / VEGFR3

RQ4081 100 ug
EUR 356.15
Description: Fms-related tyrosine kinase 4, also known as FLT4 or VEGFR3, is a protein which in humans is encoded by the FLT4 gene. It is mapped to 5q35.3. This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. FLT4 has an essential role in the development of the embryonic cardiovascular system before the emergence of the lymphatic vessels. It has been found that FLT4, which provides proangiogenic signaling when expressed on endothelium, may also have antiangiogenic properties when expressed at an avascular site by nonendothelial cells. FLT4 is also regarded as a regulator of vascular network formation.

VEGF Receptor 3 Antibody / VEGFR3

R32892 100 ug
EUR 356.15
Description: Fms-related tyrosine kinase 4, also known as FLT4 or VEGFR3, is a protein which in humans is encoded by the FLT4 gene. It is mapped to 5q35.3. This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. FLT4 has an essential role in the development of the embryonic cardiovascular system before the emergence of the lymphatic vessels. It has been found that FLT4, which provides proangiogenic signaling when expressed on endothelium, may also have antiangiogenic properties when expressed at an avascular site by nonendothelial cells. FLT4 is also regarded as a regulator of vascular network formation.

VEGF Recepr 2 Antibody

48346-100ul 100ul
EUR 399.6

VEGF Recepr 2 Antibody

48346-50ul 50ul
EUR 286.8

Antibody for Human VEGF

SPC-1291D 0.1ml
EUR 376.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is unconjugated.

Antibody for Human VEGF

SPC-1291D-A390 0.1ml
EUR 433.2
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 390.

Antibody for Human VEGF

SPC-1291D-A488 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 488.

Antibody for Human VEGF

SPC-1291D-A565 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 565.

Antibody for Human VEGF

SPC-1291D-A594 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 594.

Antibody for Human VEGF

SPC-1291D-A633 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 633.

Antibody for Human VEGF

SPC-1291D-A655 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 655.

Antibody for Human VEGF

SPC-1291D-A680 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 680.

Antibody for Human VEGF

SPC-1291D-A700 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 700.

Antibody for Human VEGF

SPC-1291D-ALP 0.1ml
EUR 426
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Alkaline Phosphatase.

Antibody for Human VEGF

SPC-1291D-APC 0.1ml
EUR 430.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to APC .

Antibody for Human VEGF

SPC-1291D-APCCY7 0.1ml
EUR 518.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to APC/Cy7.

Antibody for Human VEGF

SPC-1291D-BI 0.1ml
EUR 428.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Biotin.

Antibody for Human VEGF

SPC-1291D-DY350 0.1ml
EUR 523.2
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 350.

Antibody for Human VEGF

SPC-1291D-DY405 0.1ml
EUR 494.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 405.

Antibody for Human VEGF

SPC-1291D-DY488 0.1ml
EUR 471.6
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 488.

Antibody for Human VEGF

SPC-1291D-DY594 0.1ml
EUR 476.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 594.

Antibody for Human VEGF

SPC-1291D-DY633 0.1ml
EUR 464.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 633.

Antibody for Human VEGF

SPC-1291D-FITC 0.1ml
EUR 423.6
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to FITC.

Antibody for Human VEGF

SPC-1291D-HRP 0.1ml
EUR 418.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to HRP.

Antibody for Human VEGF

SPC-1291D-P594 0.1ml
EUR 440.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to PE/ATTO 594.

Antibody for Human VEGF

SPC-1291D-PCP 0.1ml
EUR 430.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to PerCP.

Antibody for Human VEGF

SPC-1291D-RPE 0.1ml
EUR 429.6
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to RPE .

Antibody for Human VEGF

SPC-1291D-STR 0.1ml
EUR 430.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Streptavidin.

VEGF Receptor 1 Antibody

48718-100ul 100ul
EUR 399.6

VEGF Receptor 1 Antibody

48718-50ul 50ul
EUR 286.8

VEGF Receptor 2 Antibody

48823-100ul 100ul
EUR 399.6

VEGF Receptor 2 Antibody

48823-50ul 50ul
EUR 286.8

Mouse Anti Human Vegf Receptor 1 Monoclonal Antibody

CABT-47861MH 0.1 mg
EUR 1070.4

Insula Lysate

XBL-10139 0.1 mg
EUR 663.9
Description: Human Insula tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human Insula tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the Insula tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The Insula tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

VEGF-B Polyclonal Antibody

ABP52694-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of VEGF-B from Human, Mouse, Rat. This VEGF-B antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-B at AA range: 60-140

VEGF-B Polyclonal Antibody

ABP52694-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of VEGF-B from Human, Mouse, Rat. This VEGF-B antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-B at AA range: 60-140

VEGF-B Polyclonal Antibody

ABP52694-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of VEGF-B from Human, Mouse, Rat. This VEGF-B antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human VEGF-B at AA range: 60-140

 

Engineering a novel IgG-like bispecific antibody towards enterovirus A71

 

Frequent outbreaks of enterovirus A71 (EVA71) happen within the Asia-Pacific space, and these are carefully related to extreme neurological signs in younger kids. No efficient antiviral remedy is at present accessible for the therapy of EVA71 an infection. The event of monoclonal antibodies (mAbs) has demonstrated promise as a novel remedy for the prevention and therapy of infectious illnesses. A number of medical situations have been handled utilizing bispecific or multi-specific antibodies that acknowledge two or extra distinct epitopes concurrently. Nevertheless, bispecific or multi-specific antibodies typically encounter protein expression and product stability issues.

On this research, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral exercise in contrast with E18 or F1. Moreover, E18-F1 not solely improved survival price, but in addition decreased medical indicators in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a deadly dose of EVA71. Altogether, our outcomes reveal that E18-F1 is a straightforward format bispecific antibody with promising antiviral exercise for EVA71.

Excessive antibody ranges towards human herpesvirus-6A work together with life-style elements in a number of sclerosis growth

 

Background: An infection with human herpesvirus 6A (HHV-6A) has been instructed to extend a number of sclerosis (MS) danger. Nevertheless, potential interactions between HHV-6A and environmental/life-style danger elements for MS haven’t beforehand been studied.

Strategies: We used two Swedish population-based case-control research comprising 5993 circumstances and 5995 controls. Utilizing logistic regression fashions, topics with completely different HHV-6A antibody ranges, environmental exposures, and life-style habits have been in contrast concerning MS danger, by calculating odds ratios (ORs) with 95% confidence intervals (CIs). Potential interactions between excessive HHV-6A antibody ranges and customary environmental exposures and life-style elements have been evaluated on the additive scale.

Outcomes: Excessive HHV-6A antibody ranges have been related to elevated danger of creating MS (OR = 1.5, 95% CI = 1.4-1.6). Concerning MS danger, vital interactions have been noticed between excessive HHV-6A antibody ranges and each smoking (attributable proportion (AP) = 0.2, 95% CI = 0.1-0.3), low ultraviolet radiation (UVR) publicity (AP = 0.3, 95% CI = 0.1-0.4), and low vitamin D ranges (AP = 0.3, 95% CI = 0.0-0.6).

Conclusion: Excessive HHV-6A antibody ranges are related to elevated MS danger and act synergistically with widespread environmental/life-style danger elements for MS. Additional analysis is required to analyze potential mechanisms underlying the interactions introduced on this research.

 

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *